KLK3 and posterior cortical atrophy: Decision-making and the selection of treatment modalities for newly diagnosed PCa are often determined by risk stratification using the Gleason score (GS), prostate-specific antigen (PSA), and clinical stage, according to several guidelines [2,3,4].